Gradia Health vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health program combining continuous glucose monitoring with nutrition coaching; prediabetes prevention for employer wellness programs competing with Virta Health and Omada.
About
Gradia Health is a digital health company providing personalized metabolic health programs that combine continuous glucose monitoring (CGM), one-on-one nutrition coaching, and lifestyle interventions to prevent and reverse chronic metabolic conditions including prediabetes, insulin resistance, and metabolic syndrome. Founded in 2020 in San Francisco, Gradia raised $4.33-6.83 million in funding and generated $1.1 million in revenue in 2024, serving patients through both employer-sponsored health benefits and direct-to-consumer program enrollment.\n\nGradia's program pairs participants with a continuous glucose monitor that provides real-time blood sugar data, then connects them with registered dietitians and health coaches who use that data to personalize meal plans and behavioral interventions. The CGM data reveals how individual participants' blood sugar responds to specific foods, exercise, sleep, and stress — enabling precision nutrition recommendations that go beyond generic dietary guidelines. Programs typically run 3-6 months and focus on sustainable lifestyle changes supported by regular coach check-ins.\n\nIn 2025, Gradia operates in the rapidly growing metabolic health digital platform market alongside Levels Health (CGM for optimization), Virta Health (type 2 diabetes reversal), Noom (behavioral weight loss), and Omada Health (preventive health coaching) for the employer wellness and direct-to-consumer metabolic health programs. The employer-sponsored wellness market is particularly active as self-insured employers recognize that preventing metabolic disease is significantly cheaper than treating its downstream consequences (heart disease, type 2 diabetes, kidney disease). Gradia's 2025 strategy focuses on growing employer contracts with self-insured mid-market companies, deepening the CGM-based coaching methodology with AI-powered insights, and expanding the clinical evidence base for the program's outcomes.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Gradia Health vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.